STOCK TITAN

Regeneron director George L. Sing sells 2,000 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Regeneron Pharmaceuticals, Inc. director George L. Sing reported sales of 2,000 common shares on November 16 and 17, 2026. On November 16, he sold 1,000 shares at a volume-weighted average price of $960.26 per share. On November 17, he sold 176 shares at $956.96 per share, 359 shares at a volume-weighted average price of $957.49 per share, and 465 shares at a volume-weighted average price of $958.11 per share. No Rule 10b5-1 plan is reported.

Indirect holding entries dated November 16 list 750 shares by his spouse, 400 shares by spouse/custodial son, and 1,000 shares by a trust for his son.

Insider SING GEORGE L
Role Director
Sold 2,000 shs ($1.92M)
Type Security Shares Price Value
Sale Common Stock 176 $956.96 $168K
Sale Common Stock F2 359 $957.49 $344K
Sale Common Stock F3 465 $958.11 $446K
Sale Common Stock F1 1,000 $960.26 $960K
Holding Common Stock -- -- --
Holding Common Stock -- -- --
Holding Common Stock -- -- --
Holdings After Transaction: Common Stock — 23,147 shares (Direct); Common Stock — 750 shares (Indirect, by Spouse); Common Stock — 400 shares (Indirect, by Spouse/Cust Son); Common Stock — 1,000 shares (Indirect, by Trust for Son)
Footnotes (3)
  1. F1. Represents volume-weighted average price of sales of 1,000 shares of Company stock on November 16, 2026 at prices ranging from $960.00 to $960.42. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
  2. F2. Represents volume-weighted average price of sales of 359 shares of Company stock on November 17, 2026 at prices ranging from $957.24 to $957.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
  3. F3. Represents volume-weighted average price of sales of 465 shares of Company stock on November 17, 2026 at prices ranging from $958.01 to $958.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
Shares sold 2,000 shares Four reported direct sales on November 16 and 17, 2026
Sale 1,000 shares at $960.26 per share November 16, 2026; volume-weighted average price
Sale 176 shares at $956.96 per share November 17, 2026
Sale 359 shares at $957.49 per share November 17, 2026; volume-weighted average price
Sale 465 shares at $958.11 per share November 17, 2026; volume-weighted average price
Indirect shares held by spouse 750 shares Holding entry dated November 16, 2026
Indirect shares held by spouse/custodial son 400 shares Holding entry dated November 16, 2026
Indirect shares held by trust for son 1,000 shares Holding entry dated November 16, 2026
volume-weighted average price financial
"volume-weighted average price of sales of 1,000 shares"
Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many REGN shares did director George L. Sing sell?

George L. Sing reported four sales totaling 2,000 shares: 1,000 shares at $960.26 per share on November 16, 2026, and 176 shares at $956.96, 359 at $957.49, and 465 at $958.11 per share on November 17. The $960.26, $957.49, and $958.11 prices were reported as volume-weighted averages.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
SING GEORGE L

(Last)(First)(Middle)
777 OLD SAW MILL RIVER ROAD

(Street)
TARRYTOWN NEW YORK 10591

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026S1,000D$960.26(1)24,147D
Common Stock11/17/2026S176D$956.9623,971D
Common Stock11/17/2026S359D$957.49(2)23,612D
Common Stock11/17/2026S465D$958.11(3)23,147D
Common Stock750Iby Spouse
Common Stock400Iby Spouse/Cust Son
Common Stock1,000Iby Trust for Son
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Represents volume-weighted average price of sales of 1,000 shares of Company stock on November 16, 2026 at prices ranging from $960.00 to $960.42. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 16, 2026 at each separate price.
2. Represents volume-weighted average price of sales of 359 shares of Company stock on November 17, 2026 at prices ranging from $957.24 to $957.76. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
3. Represents volume-weighted average price of sales of 465 shares of Company stock on November 17, 2026 at prices ranging from $958.01 to $958.13. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on November 17, 2026 at each separate price.
/s/ George L. Sing11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading